![Martin Lauriot Prévost](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profiel
Martin Lauriot Prévost is the founder and current Chairman of Ozyme SAS, which is founded in 1984.
He is also currently a Member-Supervisory Board at Nosopharm SAS.
Actieve functies van Martin Lauriot Prévost
Bedrijven | Functie | Begin |
---|---|---|
Ozyme SAS
![]() Ozyme SAS BiotechnologyHealth Technology Ozyme SAS is a distributor of reagents, instrumentation, and services in the fields of cellular biology, immunology, and molecular biology. The private company is based in Montigny-le-Bretonneux, France. and has subsidiaries in France. The French company was founded in 1984 by Martin Lauriot Prévost. | Oprichter | 01-01-1984 |
Nosopharm SAS
![]() Nosopharm SAS Pharmaceuticals: MajorHealth Technology Nosopharm SAS operates as a biotechnology company. It develops an anti-infective drug platform that is based on the medicinal chemistry of a novel antibiotic class used to cure life-threatening multi-resistant hospital-acquired infections. The company was founded by Philippe Villain-Guillot and Maxime Gualtieri in February 2009 and is headquartered in Nimes, France. | Directeur/Bestuurslid | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
Ozyme SAS
![]() Ozyme SAS BiotechnologyHealth Technology Ozyme SAS is a distributor of reagents, instrumentation, and services in the fields of cellular biology, immunology, and molecular biology. The private company is based in Montigny-le-Bretonneux, France. and has subsidiaries in France. The French company was founded in 1984 by Martin Lauriot Prévost. | Health Technology |
Nosopharm SAS
![]() Nosopharm SAS Pharmaceuticals: MajorHealth Technology Nosopharm SAS operates as a biotechnology company. It develops an anti-infective drug platform that is based on the medicinal chemistry of a novel antibiotic class used to cure life-threatening multi-resistant hospital-acquired infections. The company was founded by Philippe Villain-Guillot and Maxime Gualtieri in February 2009 and is headquartered in Nimes, France. | Health Technology |